World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 12 December 2020
Main ID:  NCT03482479
Date of registration: 22/03/2018
Prospective Registration: Yes
Primary sponsor: University of Pennsylvania
Public title: Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis LoDoNaVasc
Scientific title: Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
Date of first enrolment: February 4, 2019
Target sample size: 36
Recruitment status: Recruiting
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).  
Phase:  Phase 2
Countries of recruitment
United States
Name:     Carol McAlear, MA
Telephone: 7813214567
Name:     Peter A Merkel, MD, MPH
Affiliation:  University of Pennsylvania
Key inclusion & exclusion criteria

Inclusion Criteria:

Patients must meet all of the following criteria in order to be eligible for enrollment:

1. Criteria for diagnosis of giant cell arteritis (GCA), Takayasu's arteritis (TAK),
polyarteritis nodosa (PAN), granulomatosis with polyangiitis (GPA, Wegener's), microscopic
polyangiitis (MPA), or eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss),
as used for the VCRC longitudinal studies

a. Giant cell arteritis: According to the American College of Rheumatology (ACR) criteria
for classification of GCA, meeting at least 2 of the following 5 remaining criteria at the
time of diagnosis of GCA: Age of disease onset >50 years (required) i. New onset or new
type of localized pain in the head ii. Temporal artery abnormality (i.e. temporal artery
tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical
arteries) iii. ESR of >40 mm in the first hour by Westergren method iv. Temporal artery
biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration
or granulomatous inflammation, usually with multinucleated giant cells v. Large Vessel
Vasculitis (LVV) by angiogram or biopsy not explained by something else

b. Takayasu's arteritis: According to an adaption of the American College of Rheumatology
criteria, meeting at least 2 of the following 5 remaining criteria at the time of inclusion
of TAK: Arteriogram abnormalities compatible with TAK (includes conventional dye
angiography or MR angiography or CT angiography) (required) i. Age at disease onset =50
years ii. Claudication of extremities iii. Decreased brachial artery pulse (one or both
arteries) iv. Blood pressure difference of >10mm Hg between the arms v. Bruit over
subclavian arteritis or aorta

c. Polyarteritis nodosa: An adaption of the America College of Rheumatology criteria will
be used for the diagnosis of PAN. At the time of inclusion, one major and one minor
criteria or two major criteria or isolated cutaneous PAN must be met.

i. Major criteria (not explained by other causes):

1. Arteriographic abnormality

2. Presence of granulocyte or mixed leukocyte infiltrate in an arterial wall on biopsy

3. Mononeuropathy or polyneuropathy ii. Minor criteria (not explained by other causes)

1. Weight loss > 4 kg 2. Livedo reticularis, cutaneous ulcerations, or skin nodules 3.
Testicular pain or tenderness 4. Myalgias 5. Diastolic blood pressure >90mm Hg 6. Elevated
BUN or serum creatinine levels 7. Ischemic abdominal pain iii. Isolated cutaneous
polyarteritis nodosa

1. Biopsy-proven cutaneous PAN

d. Granulomatosis with polyangiitis: Participants can be enrolled if two of the five
modified American College of Rheumatology criteria are met: i. Nasal or oral
inflammation: painful or painless oral ulcers or purulent or blood nasal discharge ii.
Abnormal chest radiograph: nodules, fixed infiltrates, or cavities iii. Urinary
sediment: microhematuria or red cell casts iv. Granulomatous inflammation on biopsy:
granulomatous inflammation within the wall of an artery or in the perivascular area v.
ANCA positivity by enzyme immunoassay for either PR3- or MPO-ANCA e. Microscopic
polyangiitis: The following Chapel Hill Consensus Conference Definitions for MPA need
to be met: i. Necrotizing vasculitis with few or no immune deposits affects small
vessel (i.e., capillaries, venules, or arterioles) ii. Necrotizing arteritis involving
small and medium-sized arteritis may be present iii. Necrotizing glomerulonephritis is
very common iv. Pulmonary capillaritis often occurs

f. Eosinophilic granulomatosis with polyangiitis: An adaptation of the American
College of Rheumatology criteria will be used for the diagnosis of EGPA. At the time
of inclusion, four of the six items must have documented evidence: i. Asthma ii. Peak
peripheral blood eosinophilia of >10% of total WBC iii. Peripheral neuropathy
attributable to vasculitis iv. Transient pulmonary infiltrates on chest imaging
studies v. Paranasal sinus abnormalities or nasal polyposis vi. Eosinophilic
inflammation on tissue biopsy If patients have 4 of the above 6 criteria but lack
clear-cut documentation of small vessel vasculitis, they are also eligible for

2. Baseline normalized score on PROMIS Global Physical Health of 40 or lower.

3. Vasculitis in remission or very low disease activity, as defined by Physician Global
Assessment 0-1 for at least 12 weeks

4. Stable immunosuppressive therapy (including prednisone) related to vasculitis for at
least 12 weeks

5. No change in medications in the past 12 weeks made with the expectation of improving
pain, fatigue, or mood

6. No plan to change medication or a non-pharmacologic treatment regimen likely to affect
pain, fatigue, mood, or vasculitis activity during the next 12 weeks

7. Age of 18 years or older

8. Willingness and ability to comply with treatment and follow-up procedures, including
receipt of weekly phone calls from the study coordinator

9. Willingness and ability to provide informed consent -

Exclusion Criteria:

1. Change in any medication related to control of vasculitis, pain, fatigue, or mood
within the past 12 weeks (medications taken as needed must be in a stable pattern per
the patient's estimation)

2. Use of another investigational agent as part of a clinical trial within 30 days of

3. Current use of any opioid agonist including tramadol or suboxone

4. Change in vasculitis activity in the past 12 weeks, as defined by a change in
Physician Global Assessment greater than 1

5. Baseline normalized score more than 40 on PROMIS Global Physical Health

6. New major medical problem or surgery in past 12 weeks

7. Pregnancy or breastfeeding

8. Inability to provide informed consent or comply with study procedures

9. Schizophrenia or bipolar disorder

10. Poorly controlled depression or anxiety, as defined by a score of = 20 on PHQ-9

11. Liver cirrhosis

12. Significant kidney disease, defined as glomerular filtration rate <30ml/min

Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Churg-Strauss Syndrome (CSS)
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Giant Cell Arteritis
Granulomatosis With Polyangiitis
Microscopic Polyangiitis
Polyarteritis Nodosa
Takayasu Arteritis
Drug: Naltrexone Hydrochloride
Other: Placebo Comparator
Primary Outcome(s)
PROMIS Global Physical Health [Time Frame: Week 12.]
Secondary Outcome(s)
Clinical Global Impression of Improvement (CGI-I) [Time Frame: 12 weeks]
Clinical Global Impression of Severity (CGI-S) [Time Frame: 12 weeks]
PROMIS Global Physical Health [Time Frame: 9 weeks]
PROMIS Questionnaires [Time Frame: 12 weeks]
SF-36 (physical component subscore) [Time Frame: 12 weeks]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history